Chardan Capital Reaffirms Buy Rating for uniQure (NASDAQ:QURE)

Chardan Capital reiterated their buy rating on shares of uniQure (NASDAQ:QURE - Free Report) in a research report released on Friday,Benzinga reports. Chardan Capital currently has a $38.00 price target on the biotechnology company's stock.

QURE has been the topic of several other reports. Cantor Fitzgerald upgraded uniQure to a "strong-buy" rating in a research note on Monday, May 19th. Wells Fargo & Company dropped their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Guggenheim reiterated a "buy" rating and issued a $28.00 price target on shares of uniQure in a research note on Monday, May 12th. HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of uniQure in a research report on Thursday, May 29th. Finally, Wall Street Zen raised shares of uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, May 24th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $37.82.

uniQure Stock Up 4.9%

Shares of NASDAQ QURE traded up $0.71 during trading on Friday, reaching $15.20. The company had a trading volume of 491,664 shares, compared to its average volume of 1,903,539. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The business's 50-day moving average is $12.55 and its 200 day moving average is $13.01. The stock has a market cap of $832.60 million, a PE ratio of -3.06 and a beta of 0.10.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. The business had revenue of $1.57 million during the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities analysts forecast that uniQure will post -3.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. raised its stake in shares of uniQure by 453.2% in the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock worth $10,836,000 after buying an additional 502,684 shares during the period. Oppenheimer & Co. Inc. bought a new stake in uniQure during the 4th quarter worth approximately $320,000. Palumbo Wealth Management LLC purchased a new position in uniQure during the fourth quarter valued at approximately $437,000. Raymond James Financial Inc. bought a new position in shares of uniQure in the fourth quarter worth approximately $1,951,000. Finally, Northern Trust Corp increased its stake in shares of uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock worth $1,688,000 after purchasing an additional 1,923 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.